<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02771626</url>
  </required_header>
  <id_info>
    <org_study_id>CX-839-004</org_study_id>
    <nct_id>NCT02771626</nct_id>
  </id_info>
  <brief_title>Study CB-839 in Combination With Nivolumab in Patients With Melanoma, ccRCC and NSCLC</brief_title>
  <official_title>A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calithera Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calithera Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label Phase 1/ 2 evaluation of CB-839 in combination with nivolumab in
      patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label Phase 1/ 2 evaluation of CB-839 in combination with nivolumab in
      patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.

      During Phase 1, patients will be enrolled into escalating dose cohorts to determine the
      recommended phase 2 dose (RP2D).

      In Phase 2, patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung
      cancer will be enrolled into separate cohorts.

      All patients will be assessed for safety, pharmacokinetics, biomarkers and tumor response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of CB-839 and Nivolumab: Incidence of adverse events</measure>
    <time_frame>Every 28 days from study start until disease progression or unacceptable toxicity, assessed for an expected average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of CB-839 in Combination with Nivolumab: change in tumor size from baseline</measure>
    <time_frame>Every 28 days from study start until disease progression or unacceptable toxicity, assessed for an expected average of 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) of CB-839 in Combination with Nivolumab</measure>
    <time_frame>12 Weeks</time_frame>
    <description>A minimum of 9-12 patients with ccRCC, melanoma, or NSCLC will be enrolled in Dose Escalation to determine RP2D.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of CB-839 in combination with Nivolumab</measure>
    <time_frame>Every 28 days from study start until disease progression or unacceptable toxicity, assessed for an expected average of 6 months</time_frame>
    <description>Non-compartmental method of analysis will be used to analyze the plasma concentrations of CB-839.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">299</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Melanoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>CB-839 + Nivolumab Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: CB-839 administered as oral capsules twice daily in combination with standard dose nivolumab in patients with advanced/metastatic ccRCC, MEL, and NSCLC to select the recommended Phase 2 dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clear Cell RCC Naïve to Checkpoint Inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: CB-839/ nivolumab combination in patients with advanced/metastatic ccRCC who have previously received at least one TKI but are treatment naive to checkpoint modulators anti-PD-1/PD-L1, CTLA-4, or any other agent that specifically targets a T-cell checkpoint or co-stimulation pathway.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clear Cell RCC Recently Treated with Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: CB-839/ nivolumab combination in patients with advanced/metastatic ccRCC who received nivolumab in most recent treatment line that had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clear Cell RCC with Prior PD-1 Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 - Cohort 3: CB-839/ nivolumab combination in patients with advanced/metastatic ccRCC that had documented radiological disease progression while receiving an anti-PD-1/PD-L1 therapy in any prior line of therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melanoma with Prior PD-1 Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4: CB-839/ nivolumab combination in patients with unresectable or metastatic melanoma that had documented radiological disease progression while receiving an anti-PD-1 therapy in their most recent line of therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC with Prior PD-1 Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5: CB-839/ nivolumab combination with NSCLC that does not harbor an activating mutation in the epidermal growth factor receptor (EGFR) oncogene and who received nivolumab in most recent treatment line and had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-839</intervention_name>
    <description>Glutaminase inhibitor</description>
    <arm_group_label>CB-839 + Nivolumab Dose Escalation</arm_group_label>
    <arm_group_label>Clear Cell RCC Naïve to Checkpoint Inhibitors</arm_group_label>
    <arm_group_label>Clear Cell RCC Recently Treated with Nivolumab</arm_group_label>
    <arm_group_label>Clear Cell RCC with Prior PD-1 Therapy</arm_group_label>
    <arm_group_label>Melanoma with Prior PD-1 Therapy</arm_group_label>
    <arm_group_label>NSCLC with Prior PD-1 Therapy</arm_group_label>
    <other_name>Glutaminase inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>PD-1 inhibitor</description>
    <arm_group_label>CB-839 + Nivolumab Dose Escalation</arm_group_label>
    <arm_group_label>Clear Cell RCC Naïve to Checkpoint Inhibitors</arm_group_label>
    <arm_group_label>Clear Cell RCC Recently Treated with Nivolumab</arm_group_label>
    <arm_group_label>Clear Cell RCC with Prior PD-1 Therapy</arm_group_label>
    <arm_group_label>Melanoma with Prior PD-1 Therapy</arm_group_label>
    <arm_group_label>NSCLC with Prior PD-1 Therapy</arm_group_label>
    <other_name>Opdivo</other_name>
    <other_name>BMS-936558</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Addition eligibility criteria based on tumor type apply

        Inclusion Criteria:

          -  Ability to provide written informed consent in accordance with federal, local, and
             institutional guidelines

          -  Histological or cytological diagnosis of metastatic cancer or locally advanced cancer
             that is not amenable to local therapy

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

          -  Life Expectancy of at least 3 months

          -  Adequate hepatic, renal, cardiac, and hematologic function

          -  Measurable disease by RECISTv1.1 criteria

          -  Resolution of treatment-related toxicities except alopecia

        Exclusion Criteria:

          -  Unable to receive oral medications

          -  Unable to receive oral or IV hydration

          -  Intolerance to prior anti-PD-1/PD-L1 therapy

          -  Prior severe hypersensitivity reaction to another monoclonal antibody (mAb)

          -  Any other current or previous malignancy within 3 years except protocol allowed
             malignancies

          -  Chemotherapy, Tyrosine Kinase Inhibitor therapy, radiation therapy or hormonal therapy
             within 2 weeks

          -  Immunotherapy or biological therapy, or investigational agent within 3 weeks (Note:
             Some cohort exceptions allow anti-PD-1 therapy)

          -  Active known or suspected exclusionary autoimmune disease

          -  Any condition requiring systemic treatment with either corticosteroids (&gt; 10 mg daily
             prednisone equivalent) or other systemic immunosuppressive medications within 2 weeks

          -  History of known risks factors for bowel perforation

          -  Symptomatic ascites or pleural effusion

          -  Major surgery within 28 days before Cycle 1 Day 1

          -  Active infection requiring parenteral antibiotics, antivirals, or antifungals within 2
             weeks prior to first dose of study drug

          -  Patients who have HIV, Hepatitis B or C

          -  Conditions that could interfere with treatment or protocol-related procedures

          -  Active and/or untreated CNS disease or non-stable brain metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Whiting, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Calithera Biosciences, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <email>clinicaltrials@calithera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Honor Health</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Whitaker</last_name>
    </contact>
    <investigator>
      <last_name>Michael Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shermeen Poushnejad</last_name>
      <email>shermeen@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Denise Haas</last_name>
      <email>dhaas@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alice Fan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elaine Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Cancer Blood Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Hodgson</last_name>
      <email>jhodgson@universitycancer.com</email>
    </contact>
    <investigator>
      <last_name>Petros Nikolinakos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David McDermott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Lee, MD</last_name>
      <email>rjlee@partners.org</email>
    </contact>
    <investigator>
      <last_name>Richard Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>855-320-2090</phone>
    </contact>
    <investigator>
      <last_name>Geoffrey Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Caner Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulka Vaishampayan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Hull</last_name>
      <email>jennifer.hull@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Elaine Shum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Nesson</last_name>
      <email>an2843@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Voss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Gentile</last_name>
      <email>erica.gentile@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Afshin Dowlati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Cimidoro</last_name>
      <email>Rebecca.Cimildoro@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Naomi Haas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Ramsey</last_name>
    </contact>
    <investigator>
      <last_name>Kimryn Rathmell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Funda Meric-Bernstam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance/University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markeshia Lanier</last_name>
      <email>mlanier@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Scott Tykodi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Dhaene, BSN,RN</last_name>
      <email>LDhaene@nwmsonline.com</email>
    </contact>
    <investigator>
      <last_name>Jorge Chaves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RCC</keyword>
  <keyword>MEL</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Immuno-Oncology</keyword>
  <keyword>Tumor Metabolism</keyword>
  <keyword>Glutaminase</keyword>
  <keyword>Glutaminase Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

